Barclays analyst Matt Miksic downgraded Insulet (PODD) to Underweight from Equal Weight with a price target of $274, down from $316. As new competition approaches in the tubeless and patch-up automated insulin delivery category, Insulet’s multiple will see further pressure, the analyst tells investors in a research note. The firm believes rising competition will cause the stock to underperform peers on a relative basis.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet downgraded to Underweight from Equal Weight at Barclays
- Insulet price target lowered to $380 from $410 at Bernstein
- Insulet price target lowered to $365 from $388 at Goldman Sachs
- Insulet’s New Omnipod M Study Targets the Untapped Type 2 Diabetes Pump Market
- Insulet’s Omnipod SmartAdjust 2.0 Trial Wraps Up: What Investors Should Watch Next